

1 **A cost-effectiveness analysis of front-line treatment strategies in early stage follicular**
2 **lymphoma**

3

4 Joshua W.D. Tobin^{1,2,†}, Anna Crothers^{3,†}, Ti Eric Ma⁴, Peter Mollee^{1,4}, Maher K. Gandhi^{1,2},
5 Paul Scuffham³, Greg Hapgood^{1,4}

6

7 ¹Department of Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia

8 ²Mater Research Institute, University of Queensland, Brisbane, Queensland, Australia

9 ³Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland,

10 Australia

11 ⁴University of Queensland, Brisbane, Queensland, Australia

12

13 [†]The authors wish it to be known that, in their opinion, the first two authors should be
14 regarded as Joint First Authors.

15

16

17

18

19

20

21

22 **Corresponding author**

23 Dr Greg Hapgood

24 Princess Alexandra Hospital

25 199 Ipswich Road

26 Woolloongabba 4102

27 Brisbane, Australia

28 greg.hapgood@health.qld.gov.au

29 P +61 7 3176 2111 F +61 7 3176 7042

30

31 Running head: Cost effectiveness analysis of treatments in early stage FL

32

33 Keywords: cost effectiveness, follicular lymphoma, immunochemotherapy, radiotherapy,

34

35 Abstract word count: 150

36 Manuscript word count: 2953

37 Figures: 1 Tables: 5

38 References: 37

39

40 **Abstract**

41 Recent data suggests the use of radiotherapy alone (RT) in Early-Stage Follicular Lymphoma
42 is declining. Cost-effectiveness analysis of treatments has not been performed. We
43 constructed a partitioning model (15-year horizon) to compare RT, combined-modality
44 therapy (CMT) and immunochemotherapy with rituximab maintenance (ICT+RM) from a
45 PET-staged cohort from the Australian Lymphoma Alliance. Lifetime direct health care
46 costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs)
47 were calculated. AUD \$75,000 was defined as the willingness-to-pay threshold (WTP). The
48 direct healthcare costs were: RT \$12,791, CMT \$29,391 and ICT+RM \$42,644. Compared
49 with RT, CMT demonstrated minimal improvement in QALYs (+0.01) and an ICER well above
50 the WTP threshold (\$1,535,488). Compared with RT, ICT+RM demonstrated an
51 improvement in QALYs (+0.41) with an ICER of \$73,319. Modelling a 25% cost reduction
52 with a rituximab biosimilar led to further ICER reductions with ICT+RM (\$52,476). ICT+RM is
53 cost-effective in early stage FL from the Australian taxpayer perspective.

54

55

56

57

58 **Background**

59 Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoma
60 (NHL). Advanced-stage FL has a favourable median overall survival (OS) extending beyond
61 15 years but is considered incurable with conventional immunochemotherapy (ICT)(1). By
62 contrast, approximately 20% of patients present with early-stage FL and are treated with
63 curative intent (2).

64

65 Radiotherapy (RT) has traditionally been considered the standard of care for early stage FL
66 based on studies conducted before the widespread use of rituximab (3-6). These studies
67 demonstrated RT is well-tolerated, provides effective local disease control and may be
68 curative in a subset of patients (3). In an early randomised trial, there was no benefit from
69 adding chlorambucil to RT (7). Therefore, RT alone became the standard of care. Despite
70 this, the majority of patients eventually relapse, typically outside the RT field (5, 6).

71 Importantly, these studies were performed before the widespread adoption of ¹⁸F-
72 fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT).
73 Therefore, some of the relapsed patients may have had distant sites of PET-avidity at
74 diagnosis that would have correctly assigned them as advanced stage FL.

75

76 Recent registry data suggests the use of front-line RT alone is declining as treatment shifts
77 to systemic therapy with the development of rituximab (8-10). Rituximab is an anti-CD20
78 monoclonal antibody that has prolonged OS in advanced stage FL (11). The use of
79 immunochemotherapy (ICT) with rituximab maintenance (RM) in the front-line setting in
80 early stage FL mirrors the treatment approach in advanced stage FL.

81

82 In the modern era, the only randomised evidence to guide treatment is the TROG 99.03 trial
83 that reported significantly improved progression-free survival (PFS) with combined modality
84 therapy (CMT: RT +ICT) compared with RT alone (12). Although this study demonstrates
85 potential to improve PFS, those treated with systemic therapy experienced higher rates of
86 toxicity and there was no improvement in OS. Furthermore, cost-effectiveness was not
87 examined in this study. Consequently, the use of CMT in front-line management remains to
88 be universally adopted.

89

90 In addition to clinical efficacy, cost-effectiveness is an important but frequently neglected
91 consideration in facilitating informed public-policy decisions for the treatment of early stage
92 FL(13). Rituximab is one of the highest expenditures to public healthcare systems in most
93 developed economies. In the USA, rituximab has consistently been the second highest
94 expenditure Medicare part B drug since 2015, accounting for between USD \$1.5 and \$1.7
95 billion annually (US Centres for Medicare and Medicaid services, 2019). Consequently, the
96 financial burden of systemic therapy is an important consideration in early stage FL,
97 particularly as RT alone, the standard of care for decades, is more affordable (13).

98

99 Despite the variability in front-line treatments, an economic analysis of the cost
100 effectiveness of treatment approaches has not been performed in early stage FL. The
101 Australian Lymphoma Alliance (ALA) performed a real-world multicentre comparative
102 assessment of management practices in early stage FL that demonstrated that RT alone and
103 CMT had similar PFS, while ICT+RM demonstrated a significantly improved PFS (14). Here,
104 we performed economic modelling based on this dataset and aimed to estimate the cost-

105 effectiveness of front-line treatment with CMT and ICT+RM compared to RT alone for
106 patients with early stage FL.

107

108 **Methods**

109 *Model construction*

110 A four-state partitioned survival model was developed to simulate the total costs and
111 benefits of three front line treatment approaches in early stage FL: RT alone, CMT or
112 ICT+RM (immunochemotherapy and 2 years of rituximab maintenance).

113

114 The four disease states were: 1) 'Failure Free Survival' (FFS) defined as patients who remain
115 in remission with no requirement for second line treatment; 2) 'Survival with Failure'
116 defined as the requirement for retreatment for relapsed or progressive disease; 3) 'Survival
117 with transformation' defined as the event of clinical suspicion or biopsy-proven
118 transformation to aggressive lymphoma; 4) 'Death' defined as death from any cause (Figure
119 1). Once a patient fails treatment (relapse, progression or transformation), they remain in
120 that state for the rest of life. Incorporated into the model were the costs of each initial
121 treatment strategy, relapse and transformation costs.

122

123 The probability of moving between health states was evaluated on six-monthly cycles.
124 Simulation was limited to a 15-year time horizon. Treatment arms containing radiotherapy
125 (i.e. RT and CMT) were modelled to have a PFS plateau at 10 years (i.e., no further relapses)
126 representing patients remaining in the failure-free state and presumed to be cured(3, 8, 15).
127 In contrast, the ICT+RM arm was modelled with a stable relapse rate for the entire 15-year
128 simulated time horizon as there are no mature data in the era of PET imaging and rituximab

129 that demonstrates evidence of a cure fraction with non-RT containing approaches. The
130 model assumed: (1) all patients were treated with ICT at relapse; (2) at transformation, all
131 patients were treated with R-CHOP and patients under 65 years also received an autologous
132 stem cell transplantation (ASCT). Outcomes for the baseline analysis were quality-adjusted
133 life years (QALYs) and a cost-utility analysis expressed as an incremental cost-effectiveness
134 ratio (ICER).

135

136 *Clinical Data and Transition Probabilities*

137 The clinical data for this economic modelling was derived from an international multicentre
138 retrospective study of patients with early-stage FL from the ALA (14). This cohort included
139 365 patients with newly diagnosed early stage FL staged with PET-CT and bone marrow
140 biopsy. We excluded patients managed with a 'watchful waiting' approach (defined as
141 those not requiring lymphoma therapy for six months from diagnosis), patients receiving ICT
142 only and patients receiving CMT+RM. The economic model was derived from the remaining
143 242 patients treated actively with RT alone, CMT or ICT+RM (Table 1).

144

145 FFS and OS were estimated by applying Kaplan-Meier estimates for each group until median
146 follow-up. The exponential extrapolation method was uniformly applied for all treatment
147 arms and was selected on the basis of optimal fit for the standard-of-care treatment (i.e.,
148 RT) as assessed by the Akaike Information Criterion. In the base case, treatment was
149 assumed to only impact FFS with no impact on OS. This conservative assumption was made
150 to reflect the findings of the TROG 99.03 study which showed no significant OS difference
151 between treatment arms (12).

152

153 *Utilities*

154 A utility weight representing health-related quality of life was assigned to each health state.
155 Utility values for each health state were assigned based on a scale of 0 (death) to 1 (perfect
156 health)(Table 2). As utility data was not collected within the ALA cohort, we used published
157 utility values established in patients with advanced stage FL. Patients remaining in the FFS
158 state were assigned to have a utility of 0.88 and patients in the relapsed or transformed
159 disease state were assigned a utility weight of 0.74 (16, 17). Disutilities were applied during
160 cycles in which patients received treatment. No additional disutility was applied during
161 maintenance therapy (18).

162

163 *Estimating Cost*

164 An Australian tax payer's perspective was adopted to estimate costs of therapy (Table 3).
165 All costs reflect 2019 values and are reported in Australian Dollars (AUD). The costs of
166 initial work-up and subsequent follow-up were not included as these were likely to be
167 similar among treatment groups. The costs of therapy and associated administration in the
168 outpatient setting were derived from the Australian Pharmaceutical Benefits Scheme and
169 Medicare Schedule (19, 20). Calculations of a chemotherapy dose, and subsequent costs,
170 were based on a patient weight of 70kg with a body surface area of 1.7m². Given the
171 variability of ICT regimens in real world practice (e.g., R-CHOP, R-CVP, R-bendamustine,
172 rituximab monotherapy), we calculated a weighted average cost for treatments. Patients
173 who received maintenance therapy were assumed to receive rituximab every two months
174 over a two-year period (12 cycles)(21). Patients who received RT were assumed to receive
175 15 fractions (22). The cost of ASCT was derived from the Independent Hospital Pricing
176 Authority (23). Costs associated with hospitalisation from adverse events or palliative care

177 were not included in this evaluation. We performed a series of univariate sensitivity
178 analyses to explore the robustness of the model and the application of clinically relevant
179 assumptions. We altered the value of individual model variables to examine the individual
180 effects on the ICER. In the base-case analysis, annual discount rates of 5% were applied.
181 Cost effectiveness was assessed using a pre-specified willingness-to-pay threshold of AUD
182 \$75,000 per QALY gained based on recent approvals in Australia for blinatumomab,
183 brentuximab vedotin and ibrutinib (24-26).

184

185 **Results**

186 *Patient Characteristics and Clinical Outcomes*

187 The economic model was derived from a total of 242 patients with early-stage FL actively
188 treated with RT alone (n=171), CMT (n=34) or ICT+RM (n=37) in the ALA study. The median
189 follow-up for living patients was 3.5 years (range 0.25-12.8 years). Key patient
190 characteristics are provided in Table 1. The median age was 61 years. There was a similar
191 number of relapses in the RT (n=42, 25%) and CMT groups (n=9, 27%) but significantly fewer
192 events in the ICT+RM group (n=2, 5%)($P=0.009$). There was a similar number of
193 transformation events (RT n=11, 6% vs CMT n=1, 3% vs ICT+RM n=0 ($P=0.148$)) and deaths
194 (RT n=12, 7% vs CMT n=3, 5% vs ICT+RM n=2, 4%)($P=0.880$) between all three arms.

195

196 *Cost-Effectiveness Analysis*

197 Cost-effectiveness outcomes as predicted by the model with a 15-year time horizon are
198 presented in Table 4. Assuming 5% annual discounting, the total cost of treatment across
199 the time modelled was: RT \$12,791, CMT \$29,391 and ICT+RM \$42,644. The model
200 demonstrated a shorter time in the failure free health state for both RT (6.51 years) and

201 CMT (6.82 years) compared with ICT+RM (9.41 years). A QALY of 7.85 years was achieved
202 with RT. Compared with RT, no significant difference in QALYs was demonstrated for CMT
203 (7.86; +0.01) yet QALYs were significantly higher for ICT+RM (8.26, +0.41). Compared with
204 RT, the ICER for CMT was \$1,535,488 and the ICER ICT+RM was \$73,319.

205

206 *Sensitivity Analysis*

207 Univariate sensitivity analyses were performed on key variables underpinning the model
208 (Table 5). Broadly, all sensitivity analyses resulted in ICER values for CMT patients that
209 remained well above the WTP threshold of \$75,000. By contrast, ICT+RM remained
210 relatively stable across all sensitivity variables tested with ICER values remaining below the
211 WTP threshold. The ICT+RM model was sensitive to changes in the time horizon becoming
212 more cost-effective with longer simulated time horizons (15 years = \$73,319, 20 years =
213 \$62,709). Modelling for a 25% reduction in the cost of RT showed little impact on the
214 ICT+RM ICER value while modelling for a 25% reduction in the cost of rituximab resulted in
215 substantial improvement in the ICER of \$52,476 compared to the RT arm.

216

217 **Discussion**

218 Although RT has traditionally been considered the standard of care for early stage FL,
219 practices are highly variable and include CMT and systemic therapy with rituximab
220 maintenance (9). In this cost-effectiveness analysis, we analysed a real-world cohort of
221 early stage FL patients treated in the era of rituximab and PET-CT. Both CMT and ICT+RM
222 had substantially higher initial costs than RT. Modelling CMT treatment demonstrated only
223 a small increase in the time in the failure-free state; however, there was minimal change to
224 the QALYs compared with RT owing to significant disutility in this cohort due to the use of

225 systemic therapy. Resultantly, CMT was not cost-effective with ICER values well in excess of
226 the WTP threshold. By contrast, despite the higher upfront direct healthcare costs of
227 ICT+RM, the longer period spent in the failure-free state resulted in ICER values remaining
228 below the willingness-to-pay threshold. ICT+RM was a cost-effective treatment approach in
229 early stage FL from the Australian tax payer's perspective.

230

231 RT had been the standard of care in early stage FL based on retrospective data and a
232 randomised trial conducted prior to the modern era of rituximab and PET-CT imaging (3, 4,
233 6, 7, 27). As most relapses occur outside the RT field (15, 22, 28-30), the concept of adding
234 ICT to RT (CMT) was explored in the TROG 99.03 trial (12). It demonstrated that CMT
235 improved PFS compared with RT but did not show an OS benefit. Furthermore, the addition
236 of ICT was associated with more acute toxicity and the possibility of long-term toxicity.
237 Notably, despite the costs of local versus systemic therapy being so disparate, the cost-
238 effectiveness of treatment strategies has not been previously examined in early stage FL.

239

240 Our analysis was based on a retrospective multicentre study where all patients were staged
241 with PET-CT and managed in the rituximab era. This dataset represents the largest study
242 comparing outcomes in PET-staged early stage FL patients. This data showed that,
243 compared to RT alone, CMT had a similar PFS yet patients treated with ICT+RM had an
244 improved PFS. An important caveat is that treatments were not randomly assigned.
245 Unknown confounding variables among patients in treatment groups may have affected
246 results.

247

248 In this economic analysis, we examined the cost-effectiveness of CMT and ICT+RM
249 compared to RT. The modelled failure-free survival curves demonstrated no significant
250 difference between RT and CMT, consistent with the non-extrapolated cox-regression
251 analysis in the ALA cohort. As expected, with similar efficacy yet significant disutility with
252 the addition of ICT to RT, CMT was not cost-effective compared to RT. By contrast, although
253 the direct healthcare costs of ICT +RM (\$42,644) were higher than RT (\$12,791), this was
254 offset by a longer period in the failure-free state over a 15-year simulation. This occurred
255 with modelling for a cure fraction for the RT group and no cure for the ICT+RM group. The
256 high utility in the failure-free state largely explains the ICER values remaining below the
257 willingness-to-pay threshold, despite higher upfront costs. The costs of retreatment for
258 relapse or transformation in these patients were less influential factors in determining the
259 ICER. The base case conclusions of cost-effectiveness regarding both CMT and ICT+RM
260 remained unchanged in the sensitivity analyses. The model was most sensitive to changes
261 in the time horizon. This was due to treatment costs being accrued in the earliest cycles of
262 the model, while the incremental benefit of FFS for ICT+RM was accrued over time.

263

264 The costs of treatment approaches in early stage FL are broadly reducing over time. The
265 planning and delivery of RT in indolent lymphoma continues to be refined. Lower doses of
266 RT (24Gy over 12 fractions) have been shown to be non-inferior to higher doses (45Gy)(22).
267 Patients in the ALA cohort were treated with 24-30 Gy with a median of 15 fractions. We
268 examined the impact of a reduction in the cost of RT to reflect this and other efficiencies
269 that may result in the cheaper delivery of RT. The base-case findings were similar with the
270 model being relatively insensitive to changes in the cost of RT.

271

272 Similarly, a significant component of the cost of systemic therapy was rituximab (one dose =
273 \$2,250). We examined the impact of a reduction in the cost of rituximab as this has fallen
274 significantly since the introduction of biosimilar agents (31). The cost-effectiveness of
275 ICT+RM (ICER \$52,467) improved considerably with a 25% reduction in the cost of rituximab
276 in the model. Furthermore, a 25% price reduction is conservative based on the estimates
277 for other biosimilars in Australia (32). The actual price reduction may be greater; however,
278 due to commercial-in-confidence arrangements, this information is not publicly available.
279 This saving is also feasible with no price reduction and the use of 3-monthly maintenance
280 intervals rather than 2-monthly (33). Consequently, the cheaper rituximab becomes, the
281 more cost-effective ICT+RM therapy will be.

282

283 The model was designed to reflect an Australian tax payer's perspective in assessing cost-
284 effectiveness. In Australia, lymphoma treatment is universally available through a publicly
285 funded national health care system. This enabled the determination of the costs of therapy
286 and delivery from national resources (19, 20). Although the costs may differ internationally,
287 the results remain broadly generalisable given the costs incurred related to time in the
288 failure-free state.

289

290 Several assumptions were made in our model. Consistent with current practice, we
291 assumed that at transformation, patients <65 years would proceed to ASCT after ICT, while
292 patients >65 years would receive ICT only (34). Due to the similar rates of the rare event of
293 transformation between groups, the model remained largely unchanged by changes to this
294 assumption on univariate sensitivity analysis. Costs associated with adverse events, which
295 are more common in systemic treatment, were not included. RT is well tolerated with low

296 rates of early and late toxicity (12, 29). Conversely, systemic therapy is associated with
297 more frequent acute toxicity (12); however inpatient or supportive care of adverse events is
298 uncommon and economic modelling of similarly-treated patients with advanced-stage FL
299 has shown these adverse events contribute minimally to direct healthcare costs of therapy
300 (35). The impact on cost-effectiveness of both short and long-term toxicities is often
301 burdened by decreased quality of life, which is reflected in the disutility assigned to both the
302 'failure' health state and the disutility applied in the simulation during treatment periods.
303 We used an average cost of commonly used systemic regimens (BR, R-CHOP, R-CVP and
304 rituximab monotherapy) reflecting variable clinical practice and similar PFS among therapies
305 from previous datasets (9, 14).

306

307 To our knowledge, this is the first economic analysis of front-line treatment approaches in
308 early stage FL. Although the TROG 99.03 study demonstrated a PFS advantage with CMT
309 compared to RT alone, other measures, such as cost and toxicity, are pertinent when
310 considering the widespread application of this approach. Our data demonstrated that the
311 significant initial cost of ICT+RM was offset by improvements in FFS and subsequently
312 improved utility over the long-time horizon experienced in these patients. This suggests
313 that ICT+RM can be cost-effective despite the substantially higher upfront costs. Rituximab
314 monotherapy is a promising candidate in conjunction with RT and currently under
315 investigation in a randomised trial in early stage FL(36). Modelling a conservative 25% price
316 reduction for rituximab with the introduction of biosimilars, ICT+RM was more cost-
317 effective, demonstrating that the cheaper rituximab becomes, the more cost-effective
318 systemic therapy will be. Future clinical trials in early stage FL should include measures of
319 cost-effectiveness to facilitate public-policy and reimbursement decisions.

320

321

322 **Authorship**

323 **Conception and design:** JWDT, MG, GH.

324 **Collection and assembly of data:** JWDT, AC, EM, MG, PS, GH

325 **Data analysis and interpretation:** JWDT, AC, MG, PS, GH

326 **Manuscript writing:** All authors

327 **Final approval of manuscript:** All authors

328

329

330 **Conflict of interest statements:**

331 PM: Advisory Boards: Celgene, Janssen and Amgen, Pfizer. Trial support: Janssen.

332 The remaining authors declare no competing financial interest.

333 **Funding source:** The study was supported by an educational grant from Gilead (MKG) and

334 the Mater Foundation.

335

336

337 **Figures**

338

339

340

341

342

343

344


345

346

347 **Figure 1.** Four-state partitioning model for estimating lifetime health costs of early-stage FL

348 patients.

349



350 **Table Legend**

351 **Table 1.** Clinical characteristics of 242 early stage FL patients from the ALA Cohort.

	RT (N = 171)	CMT (N = 34)	ICT + RM (N = 37)	Overall (N= 242)
Age at Diagnosis (years)	62	54	60	61
Male	96 (56%)	14 (41%)	23 (62%)	133 (55%)
Female	75 (44%)	20 (59%)	14 (38%)	109 (45%)
Stage I	125 (73%)	21 (62%)	11 (30%)	157 (65%)
Stage II	46 (27%)	13 (38%)	26 (70%)	85 (35%)
Transformation	11 (6%)	1 (3%)	0 (0%)	12 (5%)
Relapse	42 (25%)	9 (27%)	2 (5%)	53 (22%)
Deaths	12 (7%)	3 (5%)	2 (4%)	17 (7%)
Median follow-up (years)	3.5	5.4	3.2	3.5

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394 **Table 2.** Quality of life adjustments applied in the partitioning model

	Utility weights	References
Failure Free Survival Utility	0.88	Prettyjohns et al. 2018 (17)
Progression without Death Utility	0.74	Prettyjohns et al. 2018(17)
Radiation Disutility	- 0.05	Authors' assumption
Systemic Therapy Disutility	- 0.15	Papaioannou et al. 2012 (16)
Autologous Stem Cell Transplant Disutility	- 0.20	Hornberger et al. 2008 (37)

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421 **Table 3.** Cost estimates for front-line therapy from an Australian tax payer perspective

Treatment Regimen	Drug Cost Per Treatment Cycle	Related MBS Items	Day-care Costs per Cycle	Number of Cycles	Total Cost
Radiation					
Simulation for IMRT	-	15555	\$638.50	1	\$6,612.35
IMRT Dosimetry Plan	-	15565	\$3,283.45	1	
Treatment	-	15275	\$158.00	15	
Treatment Verification	-	15715	\$66.20	15	
Systemic Therapy					
BR	\$5,240.00	13921,13924	\$175.25	6	\$32,491.50
R-CHOP	\$2,610.00	13921	\$110.80	6	\$16,324.80
R-CVP	\$2,500.00	13921	\$110.80	6	\$15,664.80
R-monotherapy	\$2,250.00	13921	\$110.80	4	\$9,443.20
Weighted Systemic	-	-	-	-	\$17,179.16
Other					
Rituximab maintenance	\$2,250.00	13921	\$110.80	12	\$20,229.60
ASCT	-	-	-	-	\$45,638.63

422
 423 MBS – Medicare benefits schedule; IMRT - Intensity-modulated radiation therapy; BR -bendamustine rituximab; R-CHOP –
 424 rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; R-CVP – rituximab, cyclophosphamide, vincristine,
 425 prednisolone; R-Monotherapy – Rituximab monootherapy; ASCT – Autologous Stem Cell Transplant.
 426

427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452

453 **Table 4.** Comparison of healthcare costs, quality-adjusted life-years and cost-effectiveness between
454 front-line therapies in early stage FL
455

Treatment	Cost		Survival		QALY		ICER (\$ per QALY) ¹
	Total	Δ Costs ¹	FFS (Yr)	Δ FFS ¹	Total	Δ QALY ¹	
RT	\$12,791	-	6.51	-	7.85	-	Reference case
CMT	\$29,391	\$16,660	6.82	+0.30	7.86	+0.01	\$1,535,488
ICT + RM	\$42,644	\$29,657	9.41	+2.90	8.26	+0.41	\$73,319

456 ¹ Compared with RT

457 CMT – combined modality therapy, QALY – quality-adjusted life years; ICER incremental cost-effectiveness
458 ratio (ICER); FFS – failure-free survival; RT – radiotherapy; ICT+RM – immunochemotherapy with rituximab
459 maintenance

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

Table 5. Univariate sensitivity analysis of cost-effectiveness model

	Total costs			Total QALY			ICER (\$ per QALY) ¹	
	RT	CMT	ICT+RM	RT	CMT	ICT+RM	CMT	ICT+RM
Base case	\$12,791	\$29,391	\$42,644	7.85	7.86	8.26	\$1,535,488	\$73,319
Discounting								
No Discounting	\$14,063	\$30,416	\$44,249	10.80	10.84	11.43	\$396,494	\$48,143
Time Horizon								
10 years	\$12,718	\$29,368	\$42,644	6.24	6.23	6.52	Dominant	\$108,815
20 years	\$12,822	\$29,401	\$42,644	8.93	8.95	9.40	\$625,382	\$62,709
Cost of radiation								
25% decrease in cost	\$11,137	\$27,738	\$42,644	7.85	7.86	8.26	\$1,535,488	\$77,379
25% increase in cost	\$14,444	\$31,044	\$42,644	7.85	7.86	8.26	\$1,535,488	\$69,260
Cost of rituximab								
25% decrease in cost	\$11,676	\$25,099	\$33,043	7.85	7.86	8.26	\$1,241,586	\$52,476
25% increase in cost	\$13,905	\$33,683	\$52,246	7.85	7.86	8.26	\$1,829,390	\$94,163
Treatment disutility								
No disutility	\$12,791	\$29,391	\$42,644	7.88	7.92	8.29	\$373,374	\$71,454
Treatment for patients who transform								
All treated with ASCT	\$12,972	\$29,449	\$42,644	7.85	7.86	8.26	\$1,514,570	\$72,856
No ASCT	\$12,488	\$29,295	\$42,644	7.85	7.86	8.26	\$1,570,939	\$74,092
Extrapolation of FFS								
Weibull	\$13,887	\$29,091	\$42,644	7.78	7.88	8.26	\$159,957	\$60,591
Lognormal	\$12,850	\$28,863	\$42,644	7.84	7.89	8.26	\$340,553	\$71,489
Log-logistic	\$13,210	\$28,985	\$42,644	7.82	7.88	8.26	\$262,401	\$67,307
Cure model for patients treated with RT and CMT								
All groups progress after 10 yrs	\$12,987	\$29,617	\$42,644	7.82	7.83	8.26	\$1,563,918	\$67,361

¹ Compared with RT

CMT – combined modality therapy, ICER incremental cost-effectiveness ratio (ICER); FFS – failure-free survival; RT – radiotherapy; ICT – immunochemotherapy; ICT+RM – immunochemotherapy with rituximab maintenance; ASCT – autologous stem cell transplant

References

1. Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. *Blood*. 2013;122(6):981-987.
2. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. *Blood*. 2004;104(5):1258-1265.
3. Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. *J Clin Oncol*. 1996;14(4):1282-1290.
4. Spry NA, Lamb DS, Vaughan Hudson G, Easterling MJ, MacLennan KA, Jelliffe AM. Localized grade I non-Hodgkin's lymphoma: results of treatment with radiotherapy alone in 88 patients. *Clin Oncol (R Coll Radiol)*. 1989;1(1):33-38.
5. Guadagnolo BA, Li S, Neuberg D, Ng A, Hua L, Silver B, et al. Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy. *Int J Radiat Oncol Biol Phys*. 2006;64(3):928-934.
6. Campbell BA, Voss N, Woods R, Gascoyne RD, Morris J, Pickles T, et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. *Cancer*. 2010;116(16):3797-3806.
7. Kelsey SM, Newland AC, Hudson GV, Jelliffe AM. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. *Med Oncol*. 1994;11(1):19-25.
8. Pugh TJ, Ballonoff A, Newman F, Rabinovitch R. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis. *Cancer*. 2010;116(16):3843-3851.
9. Friedberg JW, Byrtek M, Link BK, Flowers C, Taylor M, Hainsworth J, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. *J Clin Oncol*. 2012;30(27):3368-3375.
10. Vargo JA, Gill BS, Balasubramani GK, Beriwal S. What is the optimal management of early-stage low-grade follicular lymphoma in the modern era? *Cancer*. 2015;121(18):3325-34.
11. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. *Blood*. 2005;105(4):1417-1423.
12. MacManus M, Fisher R, Roos D, O'Brien P, Macann A, Davis S, et al. Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03. *J Clin Oncol*. 2018;36(29):2918-2925.
13. Yang JC, Yahalom J. Early-Stage Follicular Lymphoma: What Is the Preferred Treatment Strategy? *J Clin Oncol*. 2018;36(29):2904-2906.
14. Tobin JWD, Rule G, Colvin K, Calvente L, Hodgson D, Bell S, et al. Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. *Blood Adv*. 2019;3(19):2804-2811.
15. Lo A, Campbell BA, Pickles T, Aquino-Parsons C, Sehn LH, Connors J, et al. Long-Term Outcomes for Patients With Limited-Stage Follicular Lymphoma: Update of a Population-based Study. *Blood*. 2020;136(8):1006-1010.
16. Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of

- Technology Appraisal No. 110): a systematic review and economic evaluation. Health technology assessment (Winchester, England). 2012;16(37):1-253, iii-iv.
17. Prettyjohns M, Hoskin P, McNamara C, Linch D. The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma. *Br J Haematol*. 2018;180(1):52-59.
 18. Pettengell R, Donatti C, Hoskin P, Poynton C, Kettle PJ, Hancock B, et al. The impact of follicular lymphoma on health-related quality of life. *Ann Oncol*. 2008;19(3):570-576.
 19. Australian Government Department of Health. Australian Pharmaceutical Benefits Scheme 2019. Available from: <http://www.pbs.gov.au/pbs/home>. Accessed 11 June 2020.
 20. Australian Government Department of Health. MBS Online: Medical Benefits Scheme 2019. Available from: <http://www.mbsonline.gov.au>. Accessed 11 June 2020.
 21. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. *Lancet*. 2011;377(9759):42-51.
 22. Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. *Radiother Oncol*. 2011;100(1):86-92.
 23. Independent Hospital Pricing Authority. National Efficient Price Determination 2018-19, Appendix H - Price weights for admitted acute patients - AR-DRG V9.0, Independent Hospital Pricing Authority 2018. Available from: <https://www.ihsa.gov.au/publications/national-efficient-price-determination-2018-19>. Accessed 11 June 2020.
 24. Australian Government Department of Health. Ibrutinib Public Summary Document (PSD) March 2018 PBAC Meeting Pharmaceutical Benefits Scheme 2018. Available from: <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2018-03/ibrutinib-psd-march-2018>. Accessed 11 June 2020.
 25. Australian Government Department of Health. Brentuximab Vedotin Public Summary Document (PSD) November 2018 PBAC Meeting Pharmaceutical Benefits Scheme 2018. Available from: <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2018-11/Brentuximab-Vedotin-psd-november-2018>. Accessed 11 June 2020.
 26. Australian Government Department of Health. Blinatumomab Public Summary Document (PSD) July 2018 PBAC Meeting Pharmaceutical Benefits Scheme 2018 Available from: <http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2018-07/Blinatumomab-psd-july-2018>. Accessed 11 June 2020.
 27. Wilder RB, Jones D, Tucker SL, Fuller LM, Ha CS, McLaughlin P, et al. Long-term results with radiotherapy for Stage I-II follicular lymphomas. *Int J Radiat Oncol Biol Phys*. 2001;51(5):1219-1227.
 28. Hoskin PJ, Kirkwood AA, Popova B, Smith P, Robinson M, Gallop-Evans E, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. *Lancet Oncol*. 2014;15(4):457-463.
 29. Barzenje DA, Cvancarova Smastuen M, Liestol K, Fossa A, Delabie J, Kolstad A, et al. Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years. *PloS one*. 2015;10(7):e0131158.

30. Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, et al. Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: a collaborative study by ILROG. *Blood*. 2019;133(3):237-245.
31. Gulácsi L, Brodszky V, Baji P, Rencz F, Péntek M. The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries. *Adv Ther*. 2017;34(5):1128-1144.
32. Gregory GP, Carrington C, Cheah CY, Hawkes EA, Irving IM, Siderov J, et al. A consensus statement on the use of biosimilar medicines in hematology in Australia. *Asia Pac J Clin Onco*. 2020; 16(4): 211-221.
33. Van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. *Blood*. 2006;108(10):3295-3301.
34. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: B-cell lymphomas. 2018. Version 4. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 11 June 2020.
35. Soini E, Martikainen J, Nousiainen T. Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. *Ann Oncol*. 2011;22(5):1189-1197.
36. US National Library of Medicine. ClinicalTrials.gov. Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma. Available from: <https://clinicaltrials.gov/ct2/show/NCT01473628>. Accessed 11 June 2020.
37. Hornberger J, Reyes C, Lubeck D, Valente N. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. *Leuk. Lymphoma*. 2008;49(2):227-236.